• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Gene expression signatures for tailoring adjuvant chemotherapy of luminal breast cancer: stronger evidence, greater trust.

作者信息

Piccart M J, Kalinsky K, Gray R, Barlow W E, Poncet C, Cardoso F, Winer E, Sparano J

机构信息

Institut Jules Bordet Brussels, Université Libre de Bruxelles (ULB), Brussels, Belgium; Breast International Group(BIG)-aisbl, Brussels, Belgium.

Winship Cancer Institute, Emory University, Atlanta, USA.

出版信息

Ann Oncol. 2021 Sep;32(9):1077-1082. doi: 10.1016/j.annonc.2021.05.804. Epub 2021 May 31.

DOI:10.1016/j.annonc.2021.05.804
PMID:34082017
Abstract
摘要

相似文献

1
Gene expression signatures for tailoring adjuvant chemotherapy of luminal breast cancer: stronger evidence, greater trust.用于指导腔面型乳腺癌辅助化疗的基因表达特征：证据更充分，信心更坚定。
Ann Oncol. 2021 Sep;32(9):1077-1082. doi: 10.1016/j.annonc.2021.05.804. Epub 2021 May 31.
2
[Are the new breast cancer subtypes (luminal A, B etc.) of practical impact? Yes].新的乳腺癌亚型（腔面A型、B型等）有实际影响吗？答案是肯定的。
Dtsch Med Wochenschr. 2013 Oct;138(41):2096. doi: 10.1055/s-0033-1349531. Epub 2013 Oct 1.
3
[Are the new breast cancer subtypes (luminal A, B etc.) of practical impact? No].[新的乳腺癌亚型（管腔A型、B型等）有实际影响吗？没有]。
Dtsch Med Wochenschr. 2013 Oct;138(41):2097. doi: 10.1055/s-0033-1349530. Epub 2013 Oct 1.
4
High-Risk Premenopausal Luminal A Breast Cancer Patients Derive no Benefit from Adjuvant Cyclophosphamide-based Chemotherapy: Results from the DBCG77B Clinical Trial.高风险绝经前管腔 A 型乳腺癌患者从基于环磷酰胺的辅助化疗中无法获益：DBCG77B 临床试验的结果。
Clin Cancer Res. 2017 Feb 15;23(4):946-953. doi: 10.1158/1078-0432.CCR-16-1278. Epub 2016 Sep 6.
5
Triple-negative phenotype is of adverse prognostic value in patients treated with dose-dense sequential adjuvant chemotherapy: a translational research analysis in the context of a Hellenic Cooperative Oncology Group (HeCOG) randomized phase III trial.三阴性表型在接受密集剂量序贯辅助化疗的患者中具有不良预后价值：希腊肿瘤协作组（HeCOG）随机 III 期试验背景下的转化研究分析。
Cancer Chemother Pharmacol. 2012 Feb;69(2):533-46. doi: 10.1007/s00280-011-1730-9. Epub 2011 Sep 8.
6
Defining optimal duration and predicting benefit from chemotherapy in patients with luminal-like subtypes.确定管腔样亚型患者化疗的最佳疗程并预测化疗获益
Breast. 2015 Nov;24 Suppl 2:S136-42. doi: 10.1016/j.breast.2015.07.033. Epub 2015 Aug 29.
7
Adjuvant chemotherapy is not for everyone.辅助化疗并非适用于所有人。
Breast Cancer Res Treat. 2010 Aug;123(1):159-62. doi: 10.1007/s10549-010-0964-2. Epub 2010 Jun 12.
8
Endocrine therapy in 2009: consideration of the tumor and the host.2009年的内分泌治疗：肿瘤与宿主的考量
Oncology (Williston Park). 2009 Feb;23(2):150-1, 154.
9
Use of adjuvant chemotherapy in hormone receptor-positive breast cancer patients with or without the 21-gene expression assay.激素受体阳性乳腺癌患者是否使用 21 基因表达检测的辅助化疗。
Breast Cancer Res Treat. 2018 Jul;170(1):69-76. doi: 10.1007/s10549-018-4740-z. Epub 2018 Mar 8.
10
Chemotherapy regimens in early breast cancer: major controversies and future outlook.早期乳腺癌的化疗方案：主要争议和未来展望。
Expert Rev Anticancer Ther. 2013 Feb;13(2):165-78. doi: 10.1586/era.12.172.

引用本文的文献

1
MammaPrint predicts chemotherapy benefit in HR+HER2- early breast cancer: FLEX Registry real-world data.MammaPrint预测HR+HER2-早期乳腺癌患者化疗获益：FLEX注册研究的真实世界数据。
JNCI Cancer Spectr. 2025 Sep 1;9(5). doi: 10.1093/jncics/pkaf079.
2
Correlation between histopathological features and recurrence score according to menopausal status in HR+/HER2- breast cancer patients: a retrospective study.HR+/HER2-乳腺癌患者组织病理学特征与复发评分按绝经状态的相关性：一项回顾性研究
Explor Target Antitumor Ther. 2025 Jul 18;6:1002331. doi: 10.37349/etat.2025.1002331. eCollection 2025.
3
Genomic landscape of breast cancer in elderly patients.
老年乳腺癌患者的基因组图谱
NPJ Breast Cancer. 2025 Jul 10;11(1):70. doi: 10.1038/s41523-025-00781-4.
4
Risk Assessment Using Gene Expression Profiling Correlates with Clinical Prognosis Estimation in Hormone Receptor-Positive/HER2-Negative Early Breast Cancer.利用基因表达谱进行风险评估与激素受体阳性/人表皮生长因子受体2阴性早期乳腺癌的临床预后估计相关。
Breast Care (Basel). 2025 Apr 14:1-8. doi: 10.1159/000545785.
5
Refining prognostic tools for luminal breast cancer: genetic insights and comprehensive analysis.优化管腔型乳腺癌的预后评估工具：遗传学见解与综合分析
ESMO Open. 2025 Apr 29;10(5):105080. doi: 10.1016/j.esmoop.2025.105080.
6
Impact of race/ethnicity on MammaPrint genomic assay risk and prognosis in early breast cancer: A National Cancer Data Base analysis.种族/族裔对早期乳腺癌中MammaPrint基因检测风险及预后的影响：一项国家癌症数据库分析
Cancer. 2025 Mar 1;131(5):e35771. doi: 10.1002/cncr.35771.
7
A Review on Integrating Breast Cancer Clinical Data: A Unified Platform Perspective.整合乳腺癌临床数据综述：统一平台视角
Curr Treat Options Oncol. 2025 Jan;26(1):1-13. doi: 10.1007/s11864-024-01285-2. Epub 2025 Jan 3.
8
Development and Validation of Data-Driven Estimates of Recurrence Risk and Treatment Benefit in Early Breast Cancer.早期乳腺癌复发风险和治疗获益的数据驱动估计值的开发与验证
J Clin Oncol. 2025 Mar 10;43(8):899-902. doi: 10.1200/JCO-24-02452. Epub 2024 Dec 12.
9
Cell Populations in Human Breast Cancers are Molecularly and Biologically Distinct with Age.人类乳腺癌中的细胞群体在分子和生物学上随年龄而不同。
Res Sq. 2024 Oct 15:rs.3.rs-5167339. doi: 10.21203/rs.3.rs-5167339/v1.
10
Towards targeting the breast cancer immune microenvironment.针对乳腺癌免疫微环境。
Nat Rev Cancer. 2024 Aug;24(8):554-577. doi: 10.1038/s41568-024-00714-6. Epub 2024 Jul 5.